K. A. Blum

Docetaxel Combined With Trastuzumab Is an Active Regimen in HER-2 3+ Overexpressing and Fluorescent In Situ Hybridization–Positive Metastatic Breast Cancer: A Multi-Institutional Phase II Trial

Karen L. Tedesco, Ann D. Thor, Douglas H. Johnson et al. · Journal of Clinical Oncology · 2004 · 111 citations

Medicine, Oncology, Pharmacology +17

Theiler's Virus Growth in Murine Macrophage Cell Lines Depends on the State of Differentiation

Mary Lou Jelachich, Pradip K. Bandyopadhyay, K. A. Blum et al. · Virology · 1995 · 53 citations

Life Sciences, Cell Biology, Microbiology +9

Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study.

John C. Byrd, K. A. Blum, Jan A. Burger et al. · Journal of Clinical Oncology · 2011 · 34 citations

Medicine, Oncology, Pharmacology +16

A phase II study of bortezomib in relapsed Hodgkin lymphoma: Preliminary results of CALGB 50206

K. A. Blum, Jeffrey L. Johnson, Donna Niedzwiecki et al. · Journal of Clinical Oncology · 2006 · 12 citations

Medicine, Hematology, Oncology +15

Pharmacologically derived schedule of flavopiridol has significant efficacy in refractory, genetically high risk chronic lymphocytic leukemia (CLL)

John C. Byrd, T. S. Lin, James T. Dalton et al. · Journal of Clinical Oncology · 2006 · 10 citations

Medicine, Pharmacokinetics, Pharmacology +14